Stock market analyst Salil Sharma is of the view that investors can buy Ranbaxy Laboratories Ltd stock with short term target of Rs 470.

Mr. Sharma said that the interested investors can buy the stock with stop loss of Rs 442.

Today, the shares of the company opened at Rs 440 on the Bombay Stock Exchange (BSE). The share price has seen a 52-week high of Rs 538 and a low of Rs 240 on BSE.

Current EPS & P/E ratio stood at 16.19 and 28.11 respectively.

Ranbaxy Laboratories (Ranbaxy) and Daiichi Sankyo Company (Daiichi Sanlcyo), on June 10, declared that Ranbaxy has introduced a generic version of Prasugrel in the Indian market.

The product named prasita is an antiplatelet agent preventing atherothrombotic events in sufferers with acute coronary syndrome undergoing percutaneous coronary intervention.

Ranbaxy South Africa (P) (Ranbaxy SA), on June 08, has rolled out Lipogen (atorvastatin) in the potencies of 10, 20, 40 and 80mg in South Africa.

The company is the first generic drug company to unveil a generic atorvastatin in the South African market.

After esomeprazole, Atorvastatin is the second biggest molecule in the South African market.